Mefruside

Mefruside
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	C03BA05 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 4-chloro-N1-methyl-N1-[(2-methyltetrahydrofuran-2-yl)methyl]benzene-1,3-disulfonamide;
CAS Number	7195-27-9 ;
PubChem CID	4047;
ChemSpider	3907 ;
UNII	X1NS9SNS92;
KEGG	D01877 ;
CompTox Dashboard (EPA)	DTXSID0048844 ;
ECHA InfoCard	100.027.785
Chemical and physical data
Formula	C13H19ClN2O5S2
Molar mass	382.87 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CCCO1)CN(C)S(=O)(=O)C2=CC(=C(C=C2)Cl)S(=O)(=O)N;
	InChI InChI=1S/C13H19ClN2O5S2/c1-13(6-3-7-21-13)9-16(2)23(19,20)10-4-5-11(14)12(8-10)22(15,17)18/h4-5,8H,3,6-7,9H2,1-2H3,(H2,15,17,18) ; Key:SMNOERSLNYGGOU-UHFFFAOYSA-N ;
	(what is this?) (verify)

Mefruside (INN) is a diuretic indicated for the treatment of edema and hypertension.^[1]

It was developed by Bayer A.G. and is sold under the tradename Baycaron.

References

^ Allen HB, Lee DA (1973). "A general practice assessment of mefruside ('Baycaron') in the treatment of oedema and hypertension". Curr Med Res Opin. 1 (9): 547–53. doi:10.1185/03007997309111720. PMID 4779251.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.